These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 16027730)
21. Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation. Willems L; Grimonpont C; Kerkhofs P; Capiau C; Gheysen D; Conrath K; Roussef R; Mamoun R; Portetelle D; Burny A; Adam E; Lefèbvre L; Twizere JC; Heremans H; Kettmann R Oncogene; 1998 Apr; 16(17):2165-76. PubMed ID: 9619825 [TBL] [Abstract][Full Text] [Related]
22. The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD. Bernard D; Monte D; Vandenbunder B; Abbadie C Oncogene; 2002 Jun; 21(28):4392-402. PubMed ID: 12080470 [TBL] [Abstract][Full Text] [Related]
23. The chicken RelB transcription factor has transactivation sequences and a tissue-specific expression pattern that are distinct from mammalian RelB. Piffat KA; Hrdlicková R; Nehyba J; Ikeda T; Liss A; Huang S; Sif S; Gilmore TD; Bose HR Mol Cell Biol Res Commun; 2001 Sep; 4(5):266-75. PubMed ID: 11529676 [TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T. Bhat GV; Temin HM Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101 [TBL] [Abstract][Full Text] [Related]
25. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Unger T; Sionov RV; Moallem E; Yee CL; Howley PM; Oren M; Haupt Y Oncogene; 1999 May; 18(21):3205-12. PubMed ID: 10359526 [TBL] [Abstract][Full Text] [Related]
26. In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation. Griffin BD; Moynagh PN Biochem J; 2006 Nov; 400(1):115-25. PubMed ID: 16792530 [TBL] [Abstract][Full Text] [Related]
27. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Leeman JR; Weniger MA; Barth TF; Gilmore TD Oncogene; 2008 Dec; 27(53):6770-81. PubMed ID: 18695674 [TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor-alpha activation of NF-kappa B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel. Martin AG; Fresno M J Biol Chem; 2000 Aug; 275(32):24383-91. PubMed ID: 10823840 [TBL] [Abstract][Full Text] [Related]
29. Transcriptional and post-transcriptional regulation of kappaB-controlled genes by pp60v-src. Cabannes E; Vives MF; Bédard PA Oncogene; 1997 Jul; 15(1):29-43. PubMed ID: 9233775 [TBL] [Abstract][Full Text] [Related]
30. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death. Zong WX; Farrell M; Bash J; Gélinas C Oncogene; 1997 Aug; 15(8):971-80. PubMed ID: 9285692 [TBL] [Abstract][Full Text] [Related]
31. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity. Rayet B; Fan Y; Gélinas C Mol Cell Biol; 2003 Mar; 23(5):1520-33. PubMed ID: 12588973 [TBL] [Abstract][Full Text] [Related]
32. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Kalaitzidis D; Davis RE; Rosenwald A; Staudt LM; Gilmore TD Oncogene; 2002 Dec; 21(57):8759-68. PubMed ID: 12483529 [TBL] [Abstract][Full Text] [Related]
33. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras. Gapuzan ME; Schmah O; Pollock AD; Hoffmann A; Gilmore TD Oncogene; 2005 Sep; 24(43):6574-83. PubMed ID: 16027734 [TBL] [Abstract][Full Text] [Related]
34. Transcriptional regulation of IL-8 by Staphylococcus aureus in human conjunctival cells involves activation of AP-1. Venza I; Cucinotta M; Caristi S; Mancuso G; Teti D Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):270-6. PubMed ID: 17197543 [TBL] [Abstract][Full Text] [Related]
35. CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel. Dutta J; Fan G; Gélinas C J Virol; 2008 Nov; 82(21):10792-802. PubMed ID: 18753212 [TBL] [Abstract][Full Text] [Related]
36. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein. Chen C; Agnès F; Gélinas C Mol Cell Biol; 1999 Jan; 19(1):307-16. PubMed ID: 9858554 [TBL] [Abstract][Full Text] [Related]
37. The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site. Bost F; Caron L; Vial E; Montreau N; Marchetti I; Dejong V; Defize L; Castellazzi M; Binétruy B Oncogene; 2001 Nov; 20(50):7425-9. PubMed ID: 11704873 [TBL] [Abstract][Full Text] [Related]
38. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Gélinas C; Temin HM Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247 [TBL] [Abstract][Full Text] [Related]
39. Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Bernard D; Quatannens B; Begue A; Vandenbunder B; Abbadie C Cancer Res; 2001 Mar; 61(6):2656-64. PubMed ID: 11289144 [TBL] [Abstract][Full Text] [Related]
40. Analysis of mutations of the PITX2 transcription factor found in patients with Axenfeld-Rieger syndrome. Footz T; Idrees F; Acharya M; Kozlowski K; Walter MA Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2599-606. PubMed ID: 19218601 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]